Malaysia
Search
Sign In
Multidisciplinary
Top Medical News
Use of aspirin offers health benefits to older individuals with elevated lipoprotein(a) genotypes by preventing cardiovascular events, suggests a study.
In the updated analysis of the POSEIDON trial presented at ESMO 2022, the combination regimen comprising tremelimumab, durvalumab, and chemotherapy (T+D+CT) used in the first-line setting conferred long-term overall survival (OS) benefit in individuals with metastatic non-small-cell lung cancer (mNSCLC).
In prostate cancer patients, the initiation of androgen deprivation therapy (ADT) lowers the concentrations of 13 circulating steroids, according to a new study.
Patients with psoriasis report improved quality of life under the COVID-19 pandemic despite harsh movement restrictions, a recent study has found. Such an effect, however, may suggest that current tools do not completely capture the negative impacts of harsh lockdowns on patients’ wellbeing.
The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.
The addition of apatinib to vinorelbine appears to prolong progression-free survival in patients with advanced triple-negative breast cancer (TNBC) with failed first- or second-line treatment, as shown in the results of a phase II study.
High adherence to the palaeolithic diet helps reduce sleep apnoea in menopausal women who are overweight, with the benefit linked to weight loss, according to a secondary analysis of a trial comparing a 2-year intervention of a palaeolithic diet with a low-fat control diet according to the Nordic Nutritional Recommendations.
Special Reports
The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.
Multiple myeloma (MM) is an uncommon cancer usually afflicting those in their 70s. About 85% of these patients present with bone pain. When presenting to an orthopaedic surgeon, patients usually complain about back pain or bone pain. To differentiate between MM and regular bone pain, three criteria are looked at: the characteristic of the pain—MM-associated pain is persistent even with rest and can sometimes disturb sleep; the site of the pain—usually very generalized and covers entire back; and the patient’s general outlook—MM patients can look extremely unwell and complain of lethargy, loss of appetite, weight loss, and complain of feeling unwell in general.
A study on Systane® COMPLETE was conducted from March to April 2020. Twenty-six patients were enrolled at the beginning of the study, but only 21 patients completed the study at 1-month follow-up. The data was analysed only for those who completed the 4-week review during the study period. Systane® COMPLETE was initiated at four to six times per day, instilled into both eyes as a single therapy for dry eyes
Adalimumab soln for inj 40 mg/0.8 mL
Ravidasvir 200 mg tab
Talazoparib 0.25 mg hard cap
Patients with rare genetic diseases usually have limited treatment options if any is available. Gene therapy has been progressing tremendously especially in the treatment of challenging rare genetic diseases such as spinal muscularatrophy (SMA). Modification of genetic diseases perhaps to the point of cure may be possible with gene therapy. Two renowned experts in clinical genetics discuss gene therapies for selected deleterious genetic diseases
Conference Reports
The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.
Results of the STOP-COVID trial, presented at ERS 2022, showed no clinical outcome benefit with the dipeptidyl peptidase-1 (DPP-1) inhibitor brensocatib compared with placebo in patients hospitalized with COVID-19 in the UK.
Following negative primary results, the final follow-up of the SYMPLICITY HTN-3 trial takes a turn for the better, demonstrating significant blood pressure (BP) reductions with renal denervation (RDN) in patients with uncontrolled hypertension (HTN).
Timing of antihypertensive medication intake, be it in the morning or evening, does not appear to affect the risk of cardiovascular death or hospitalization for non-fatal myocardial infarction (MI) or non-fatal stroke, according to results of the TIME trial presented at ESC 2022.
In the 24-month follow-up results of the EMPROVE trial, treatment with the Spiration Valve System (SVS) endobronchial valve provided a sustained clinically significant benefit in disease-specific health-related quality of life (QoL) in patients with severe heterogeneous emphysema.
The risk of hypertensive disorders in pregnancy (HDP) is increased following assisted reproductive technology (ART) using frozen embryo transfer (FET) compared with after fresh embryo transfer or natural conception, according to results of a study presented at ESHRE 2022.
Compared with aspirin alone, treatment with a P2Y12 inhibitor (clopidogrel or ticagrelor) is associated with lower risks of cardiovascular (CV) death, myocardial infarction (MI), or stroke in patients with established coronary artery disease (CAD), according to the PANTHER* trial presented at ESC 2022.
Multimedia
